15 Popular Journalists Covering Biotech and Pharma

15 Popular Journalists Covering Biotech and Pharma

Biotech and pharma moves quickly, and the journalists who cover this world help make sense of science, strategy and decisions shaping the future of healthcare.

From drug approvals and clinical trials to policy decisions, research milestones and the business of life sciences, these 15 reporters bring clear, thoughtful reporting to the most important stories in the industry.

If you work in PR or communications for a life sciences company, these are the names worth following.

1. Jonathan Rockoff – Health Business Editor, The Wall Street Journal

Jonathan Rockoff covers biotech and pharmaceutical markets for The Wall Street Journal, bringing deep insight into drug-pricing strategies, biotech M&A and how policymakers influence healthcare innovation. His reporting often uncovers the tension between corporate ambitions and public policy, whether it's a pharma giant striking deals or navigating regulatory pressures.

Rockoff’s stories help readers understand the business of medicine, not just science. He breaks down complex pharma deals and pricing strategies into clear narratives, showing how corporate decisions ripple into health policy, patient access, and global market dynamics.

Recent Articles by Jonathan Rockoff:

• Pfizer and Metsera Reach Deal Expected to Top $10 Billion - Rockoff reports on Pfizer’s winning bid to acquire the weight-loss biotech Metsera, highlighting the financial terms and the competitive landscape.
• Pfizer Preps Improved Offer in Metsera Bidding War - He dives into how Pfizer raised its bid amid a heated auction for Metsera, revealing the stakes for both companies and how this shapes future obesity-drug innovation.
• Inside Pfizer’s Drug-Pricing Deal With the Trump Administration - Rockoff explains how Pfizer locked in a drug-pricing agreement with the Trump administration to avoid tariffs, exploring both its business implications and political dimensions.

2. Elaine Chen – National Biotech Reporter, STAT News

Elaine Chen at STAT News dives into biotech and pharma, showing how big scientific ideas meet corporate strategy and regulation. She's great at breaking down complex stories, making the "why it matters" clear for everyone from investors to doctors.

Her beat blends innovation, dollars, and policy – whether it’s an obesity-drug bidding war, China’s biotech surge or the FDA’s evolving role.

Recent Articles by Elaine Chen:

• “Why is Eli Lilly worth nearly $1 trillion?” - A look at how Lilly built massive value amid obesity-drug momentum and what the future might hold.
• “Chinese government’s support for biotech fuels huge rally” - Explores how state-backed biotech in China is shaping global markets and investor expectations.
• “The $10 billion question: Will Pfizer hit it big with Metsera, or have regrets?” - A deep dive into Pfizer’s acquisition of Metsera and the risks behind making such bets in obesity drug development.

3. Katherine Davis – Biotech Deals Reporter, Axios

Katherine Davis at Axios Pro Deals is the go-to reporter for the money side of biotech. She breaks down complex venture capital, M&A and private equity deals to show investors and founders what these financial moves really mean for drug development and long-term company strategy.

Her beat shines a light on how money flows through biotech - which companies are raising big rounds, who’s buying whom and how that impacts innovation in medicine.

Recent Articles by Katherine Davis:

• Sofinnova Partners closes €650M fund - Davis reports that Sofinnova, a Paris-based life sciences VC, has raised €650 million amid a volatile market, illustrating continued investor appetite for biotech innovation.
• Merck to buy Cidara Therapeutics in $9.2B deal - She covers Merck’s major acquisition of Cidara, a flu-prevention biotech, highlighting how big pharma is still banking on strategic M&A.
• The GLP-1 gold rush is just beginning - Davis dives into a rush of GLP-1–focused biotechs (beyond just Metsera), suggesting many could become targets for acquisition as obesity and metabolic disease remain hot areas.

4. Ahmed Aboulenein – U.S. Health & Pharma Policy Reporter, Reuters

Ahmed Aboulenein covers U.S. health policy, pharmaceutical regulation, and federal agency decision-making for Reuters. His reporting often sits at the intersection of politics, science and public health, especially when new policies or regulatory shifts have sweeping implications for drugmakers, clinicians and patients.

Ahmed tracks decisions made in Washington, showing how things like FDA changes or congressional debates immediately impact the entire healthcare and biotech world. His reporting quickly clarifies complex political developments.

Recent Articles by Ahmed Aboulenein:

• U.S. FDA plans to tap oncology expert Pazdur as top drug regulator - Aboulenein reports on the FDA’s move to elevate cancer-drug veteran Richard Pazdur, breaking down what this leadership shift could mean for future drug approvals.
• FDA chief urges drugmakers to remove old warnings from hormone-therapy meds - He explained the FDA Commissioner's push to update hormone-therapy labels, aiming to reflect new science and reduce patient confusion.
• Trump’s surgeon-general nominee Casey Means faces Senate grilling - Aboulenein covers the tense confirmation hearing for Casey Means, highlighting lawmakers’ concerns about her views on public health, vaccines and medical evidence.

5. Lisa Schencker – Health Care Reporter, Chicago Tribune

Lisa Schencker covers hospitals and health policy for the Chicago Tribune. She focuses on how changes in laws and hospital decisions actually affect patients and families in Illinois, making complex health debates feel real.

Lisa's articles shows readers how national health debates, like those on insurance or care limits, directly impact local people, while also looking at the financial and political forces affecting hospitals and insurers.

Recent Articles by Lisa Schencker:

• Millions could lose access to subsidized ACA plans if Obamacare changes move forward - Schencker explains how proposed changes to Affordable Care Act subsidies could raise costs for many Illinois families and what’s at stake for consumers.
• Illinois hospitals see shifts in safety grades as new Leapfrog ratings come out - She breaks down the latest hospital-safety report card, highlighting where Illinois facilities improved and where concerns remain.
• Hospitals pull back gender-affirming care for minors under Trump policies - A detailed look at how political changes are reducing access to gender-affirming care for young people, leaving many families scrambling for options.

6. Rebecca Robbins – Health & Pharma Reporter, The New York Times

Rebecca Robbins reports on medicine, drug pricing, and policy at The New York Times. She shines a light on how regulatory decisions, pricing deals, and market forces shape access to treatments and affect public health.

Robbins blends in-depth policy analysis with real-world impact. Her stories make it clear how powerful pharmaceutical companies, government negotiators and regulators influence whether people get life-changing drugs and at what cost.

Recent Articles by Rebecca Robbins:

• “R.F.K. Jr. and Drugmakers Clash Over Obesity-Drug Access” - Robbins examines criticism from Robert F. Kennedy Jr. about the pricing of obesity medications and how those comments are influencing public and regulatory conversations.
• “FDA Names Richard Pazdur Its Top Drug Regulator” - She reports on the FDA’s decision to appoint longtime oncology expert Richard Pazdur to a major leadership role, exploring how this could shape future cancer-drug approvals.
• “F.D.A. Moves to Speed Approvals for Cheaper Copycat Drugs” - Robbins details the FDA’s effort to streamline biosimilar approvals, arguing that it could lower drug costs and expand access.

7. Joseph Choi – Health Care Reporter, The Hill

Joseph Choi covers health care policy, regulatory developments and industry-politics intersections at The Hill. His reporting zeroes in on how legislative choices and agency decisions shape access to care and the broader pharma ecosystem.

Choi’s articles help communication, IR and PR professionals understand the policy levers affecting biotech and pharma narratives and the politics behind drug pricing, regulatory appointments and how government health-program changes can shift markets.

Recent Articles by Joseph Choi:

• “Vaccination rates decline across America, raising concerns among health experts” - Choi reports on falling vaccination coverage in the U.S., and explores implications for public health infrastructure and pharmaceutical demand.
• “Senate Republicans unsure of next steps on health-care reforms” - A look at how shifts in Senate alignment are delaying or changing major health-care legislation, affecting biotech and pharma sectors.
• “FDA drops hormone-therapy black-box warning, marking regulatory shift” - Choi covers the Food and Drug Administration’s decision to remove the black-box label from long-standing hormone therapies, and what this means for drug-makers and patients.

8. Maggie Fick – Global Pharmaceuticals Correspondent, Reuters

Maggie Fick at Reuters tracks the global business of pharmaceuticals, concentrating on major M&A, obesity drugs and how the world's biggest drug companies handle political and market pressures. Her reports are vital because they combine clear financial analysis with strong industry context.

She regularly breaks news on deals, pricing negotiations, regulatory tensions and executive shake-ups, offering readers a front-row view of the strategic moves shaping the next decade of drug development.

Recent Articles by Maggie Fick:

• “Novo Nordisk faces rare shareholder rebuke over board shake-up” - Fick reports on investor pushback against Novo Nordisk’s leadership decisions, highlighting the growing scrutiny of governance as the company dominates the obesity-drug market.
• “Novo Nordisk CEO signals new appetite for risk in obesity-drug deals” - A deep look at how Novo’s leadership is recalibrating its deal-making strategy amid fierce competition and rising pressure from rivals like Pfizer.
• “Pfizer sweetens offer in Metsera bidding war against Novo” - Fick breaks down the escalating race between Pfizer and Novo Nordisk to acquire Metsera, showing how obesity drugs have become the industry’s most competitive battleground.

9. Hannah Kuchler – Global Pharmaceutical Editor, Financial Times

Hannah Kuchler leads coverage on the global pharma industry for the Financial Times, tracking big-picture trends in drug-pricing, innovation and competition. Her reporting often spotlights how major drugmakers strategize around obesity, M&A and regulatory risk.

Kuchler translates high stakes deals and biotech strategy into smart, readable stories showing how global pharma players are navigating market shifts, pricing pressures and innovation pathways.

Recent Articles by Hannah Kuchler:

• “‘Not desperate’: Novo Nordisk’s new boss defends strategy” - Kuchler reports on Novo’s leadership change, and how the company is positioning itself amid fierce Metsera competition.
• “Novo Nordisk challenges Pfizer to raise offer for obesity biotech” - She unpacks the escalating bidding war between Novo and Pfizer for Metsera and what this deal could mean for the obesity drug market.
• “Roche agrees biggest-ever obesity drug deal” - Kuchler covers Roche’s $5.3 billion licensing pact with Zealand Pharma to develop a next-gen obesity treatment.

10. Anna Brown – Reporter, Endpoints News

Anna Brown covers biotech, pharma manufacturing, CDMOs, and regulatory updates for Endpoints News. Her reporting is practical, fast-moving and often centers on how industry decisions impact operations, supply chains and commercial strategy.

Brown tracks the stories that shape day-to-day biotech realities from manufacturing challenges to early signals from regulators and policy shifts. Her coverage is useful for anyone watching how infrastructure, supply and scale-up pressures affect commercial launches.

Recent Articles by Anna Brown:

• “Catalent lays off more gene therapy workers in Baltimore” - Brown reports on the latest round of job cuts at Catalent’s Baltimore site, highlighting ongoing challenges in gene therapy manufacturing.
• “As pharma pour billions in US manufacturing, CDMOs see future opportunities” - She breaks down how increased domestic manufacturing investments are reshaping demand for CDMOs and where service providers see long-term growth.
• “Abeona’s skin disease cell therapy launch stymied by false-positive sterility test” - Brown covers how a sterility testing issue disrupted Abeona’s launch plans, underscoring how manufacturing hiccups can delay commercial rollouts.

11. Helena Beer – Editor & Reporter, Hospital Pharmacy Europe

Helena Beer focuses on clinical pharmacy, medicines safety, emerging research and the evolving role of hospital pharmacists. Her articles often break down complex science into clear, practical takeaways for healthcare professionals.

Beer consistently highlights how pharmacists are driving better patient outcomes, whether through smarter use of data, new clinical practices or innovative technology. Her work is especially helpful for anyone following the future of hospital pharmacy, precision medicine and evidence-based care.

Recent Articles by Helena Beer:

• “AI could save healthcare staff 43 minutes admin time per day, pilot suggests” - Beer looks at early results from a UK pilot showing how AI tools could ease daily administrative workloads for pharmacists and clinicians.
• “PK-PD modelling in predicting small molecule drug toxicities” - A deep dive into how pharmacokinetic and pharmacodynamic modelling is improving the ability to forecast drug toxicity earlier in development.
• “Maximising hospital pharmacy: translating research into paediatric patient care” - Beer explores how new research is being applied in paediatric settings, helping hospital pharmacists deliver more precise and safer care for children.

12. David Wild – Senior Writer, Citeline / In Vivo

David Wild covers the people, ideas and technologies shaping the future of biopharma. His reporting often blends executive insight, scientific innovation and the business decisions that move the industry forward.

Wild’s articles give a clear view into how R&D leaders think, where investment is flowing and which breakthroughs are closest to real-world impact. If you follow biotech strategy, cutting-edge drug discovery or leadership shifts inside major pharma companies, his work is always worth reading.

Recent Articles by David Wild:

• “Cellprothera targeting heart regeneration where no treatment exists” - Wild explores Cellprothera’s bold push to repair damaged heart tissue using regenerative cell therapy, an area with huge unmet need and no approved options.
• “A $30m milestone and leadership handoff signal new chapter for Recursion” - A look at Recursion’s latest progress, including a key funding milestone and a leadership change that sets up the company’s next phase of growth in AI-driven drug discovery.
• “How rare disease advocates are reshaping gene therapy development” - Wild highlights the growing influence of patient advocates and how they're pushing industry and regulators to speed up access to gene therapies for rare diseases.

13. Paul Naphtali – Senior Science Writer, BioCompare

Paul Naphtali writes for BioCompare, covering molecular biology techniques, biomarker development and the tools that underpin drug discovery. His articles make highly technical science more accessible and relevant to both researchers and the broader biotech community.

Naphtali focuses on the technical "how" of biotech - from measuring DNA/RNA to finding new biomarkers. His work clarifies the lab technologies that drive progress and is essential reading for scientists and R&D teams who need to stay current on cutting-edge methods.

Recent Articles by Paul Naphtali:

• “Sample Processing for Nucleic Acid Analyses” - Naphtali explores the critical steps and best practices in preparing biological samples for RNA and DNA analysis, highlighting common pitfalls and optimization strategies.
• “Developing Novel Biomarkers with Liquid Biopsy” - He explains how liquid biopsy technologies are pushing biomarker discovery forward, enabling less invasive sampling and more dynamic monitoring of disease.
• “Predictive Markers for Drug Responses” - Naphtali dives into how predictive biomarkers can forecast how patients will respond to therapies, supporting personalized medicine and better drug development decisions.

14. Annalee Armstrong – Senior Editor, BioSpace

Armstrong covers the major biopharma storylines, including bidding wars, FDA decisions and executive changes. Her reporting combines sharp analysis with a look at the industry's human side, making complex topics like deals and policy shifts easy to understand.

Armstrong is a leading voice in biopharma journalism. She covers all the industry's biggest stories like GLP-1 pricing, major mergers and political issues, breaking them down into clear, engaging articles. Read her to get the real-time pulse of biopharma.

Recent Articles by Annalee Armstrong:

• Another Bidding War Breaks as Lundbeck Bids for Sleep Biotech Avadel - Armstrong breaks down why Lundbeck rushed into the deal, what Avadel offers, and how this could spark another biotech bidding war.
• Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal - A tough week for Korro - Armstrong lays out the clinical setback, the investor reaction, and why Novo Nordisk hit pause on the partnership.
• Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama - Pfizer has officially closed the Metsera deal, winning one of biopharma's most intense acquisition battles.

15. Vera Kovacevic – Science & Clinical Research Writer, Xtalks

Vera Kovacevic, PhD, writes clear, practical stories on clinical research, new technologies, AI in drug development and the future of patient-focused trials. She explains complex science in a simple way and helps readers see where clinical trials are headed.

Kovacevic covers the breakthroughs that will shape the next decade of clinical research — from smarter sample collection to AI-driven trial design. She brings in expert views, key trends and real-world challenges to show what’s coming next.

Recent Articles by Vera Kovacevic:

• Clinical Trials by 2030: Which Emerging Technology Will Have the Biggest Impact? - Kovacevic looks at new tools like AI, digital biomarkers and remote monitoring and explains how they could change the way clinical trials are designed and run.
• Engineering Next-Gen Radiopharmaceuticals for Precision and Safety - Kovacevic gives a simple breakdown of how radiopharmaceuticals are evolving, with new ways to improve targeting, safety and accuracy.
• Which Stage of Pharma & Biotech R&D Will Benefit Most from AI in the Next 5 Years? - Kovacevic explains how AI is shaping the R&D process and where companies expect the biggest benefits from early discovery to clinical decisions.

Why These Reporters Lead Today’s Biotech & Pharma Conversation

Biotech and pharma are changing fast - from AI-powered drug discovery to new global competition and shifting FDA priorities. In a world where science, policy and business collide, these journalists help bring clarity and trustworthy reporting.

They explain the people, decisions and breakthroughs behind the headlines, making complex topics easy to understand and showing what they mean for patients, companies and the future of healthcare.

Learn More About the Notified PR Platform

These 15 journalists are a great place to start, but the Notified PR Platform lets you quickly reach verified reporters from around the world using Smart Search technology.

And paired with GlobeNewswire’s trusted press release distribution, you can:

• Share your story with the right journalists
• Increase visibility across key audiences
• Track performance, measure impact and get cited in AI answers...

...all in one place, with one login.

Learn more about the Notified PR Platform today.